Gilead Sciences Price to Sales Ratio 2010-2022 | GILD

Historical PS ratio values for Gilead Sciences (GILD) over the last 10 years. The current P/S ratio for Gilead Sciences as of May 24, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Gilead Sciences P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-05-25 65.01 2.99
2022-03-31 59.45 $21.78 2.73
2021-12-31 71.71 $21.64 3.31
2021-09-30 68.30 $21.78 3.14
2021-06-30 66.66 $21.12 3.16
2021-03-31 61.92 $20.28 3.05
2020-12-31 55.18 $19.56 2.82
2020-09-30 59.17 $18.29 3.24
2020-06-30 71.32 $17.49 4.08
2020-03-31 68.66 $17.85 3.85
2019-12-31 59.09 $17.59 3.36
2019-09-30 57.10 $17.42 3.28
2019-06-30 60.30 $17.28 3.49
2019-03-31 57.48 $17.15 3.35
2018-12-31 54.77 $16.88 3.24
2018-09-30 67.04 $16.96 3.95
2018-06-30 61.04 $17.62 3.46
2018-03-31 64.45 $18.72 3.44
2017-12-31 60.81 $19.80 3.07
2017-09-30 68.29 $20.68 3.30
2017-06-30 59.28 $21.34 2.78
2017-03-31 56.44 $21.66 2.61
2016-12-31 59.05 $22.25 2.65
2016-09-30 64.83 $22.45 2.89
2016-06-30 67.95 $22.37 3.04
2016-03-31 74.40 $21.98 3.38
2015-12-31 81.57 $21.30 3.83
2015-09-30 78.62 $20.15 3.90
2015-06-30 93.61 $18.32 5.11
2015-03-31 78.17 $16.90 4.63
2014-12-31 75.09 $15.03 4.99
2014-09-30 84.80 $12.43 6.82
2014-06-30 66.05 $10.39 6.36
2014-03-31 56.45 $8.09 6.97
2013-12-31 59.83 $6.64 9.01
2013-09-30 50.08 $6.43 7.79
2013-06-30 40.84 $6.32 6.46
2013-03-31 38.99 $6.23 6.26
2012-12-31 29.26 $6.17 4.74
2012-09-30 26.42 $5.93 4.45
2012-06-30 20.43 $5.76 3.55
2012-03-31 19.46 $5.55 3.50
2011-12-31 16.30 $5.27 3.09
2011-09-30 15.45 $5.02 3.08
2011-06-30 16.49 $4.81 3.43
2011-03-31 16.92 $4.55 3.72
2010-12-31 14.44 $4.48 3.22
2010-09-30 14.18 $4.43 3.20
2010-06-30 13.65 $4.25 3.21
2010-03-31 18.11 $4.06 4.46
2009-12-31 17.24 $3.75 4.60
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $80.715B $27.305B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00